Jeremy Johns

TL;DR: The flagship paper of the ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium describes the generation of the integrative analyses of 2,658 whole-cancer genomes and their matching normal tissues across 38 tumour types, the structures for international data sharing and standardized analyses, and the main scientific findings from across the consortium studies.

TL;DR: It is suggested that intensified treatment of genomically aggressive localized prostate cancer may improve cure rates and numerous molecular aberrations were prognostic for disease recurrence, including several DNA methylation events, and a signature comprised of these aberration outperformed well-described prognostic biomarkers.

TL;DR: It is found that pancreatic cancer tumorigenesis is neither gradual nor follows the accepted mutation order, and changes in DNA copy number and their associated rearrangements in tumour-enriched genomes are tracked and challenged.

TL;DR: A new recurrent amplification of MYCL is identified and validated, which is associated with TP53 deletion and unique profiles of DNA damage and transcriptional dysregulation, and this data represents the first systematic relation of intraprostatic genomic heterogeneity to predicted clinical outcome.

TL;DR: Data reveal intricate crosstalk between the germ line and the epigenome of primary tumors, which may help identify germline biomarkers of aggressive disease to aid patient triage and optimize the use of more invasive or expensive diagnostic assays.